Wednesday, January 27, 2021

Repligen Company (RGEN) named price of Common Stock Shares

- Advertisement -
- Advertisement -

Repligen Company (NASDAQ: RGEN) today announced the pricing of an underwritten public offering at a public offering price of $181 per share for 1.5 million shares of its common stock.

Repligen Company has also given the underwriters a 30-day chance to buy up to 225,000 additional common stock securities, fewer discounts, and commissions at the public bidding offer. Repligen estimates the revenue from the offering to be roughly around $271.5 million before deducting the underwriting discounts and fees and other offering costs, minus any exercise of the underwriters’ choice to buy additional stock. Subject to standard closing terms, the offering is scheduled to close on or around 10 December 2020.

Repligen Company plans to use the net proceeds from this sale for working capital and other general corporate needs. Net profits from this deal can also be used to support future sales or acquisitions in supplementary entities, goods, facilities, and technology. At this time, Repligen has not entered into any agreements or commitments about any acquisitions or investments.

These shares will be offered and distributed in compliance with the Securities and Exchange Commission (S.E.C.) and an immediately effective declaration of the shelf’s registration (including the base prospect), which had been previously submitted. A preliminary supplement to the prospectus related to this bid was submitted with the S.E.C. If available, copies of the final supplement to the prospectus and the accompanying prospectus relating to this offering can be obtained from J.P. Morgan Securities L.L.C.

Repligen Corporation is a global life sciences organization that produces and commercializes very advanced bioprocessing technologies and systems that improve biological drug production processes’ performance. Biopharmaceutical device manufacturers and contract production and processing companies (CDMOs) worldwide are our main clients.

- Advertisement -

Latest news

Oil Market Was On Hold, Gold Still Unsteady

In the face of doubt about the market and progression of the Covid-19 virus, oil ended in a distributed order. U.S. light crude WTI...
- Advertisement -

Dollar Appreciated Amid Uncertainty Regarding The Stimulus Plan

The EUR/USD rate rose by 0.02 percent on Monday, January 25, and the trading session ended at the 1.2169 marks. In turn, the dollar...

Intel (INTC) Failed To Save Itself Despite Stronger Results, Comcast (CMCSA) Stabilized Despite Delaying Bond Film

Intel Corporation (INTC) decreased by -9.29% to $56.66. Shares of designer, manufacturer, and seller of essential semiconductor technologies for the cloud, smart, and connected...

Travelers Companies (TRV) Rose While United Airlines (UAL) Fell After Quarterly Results

On Thursday, The Travelers Companies Inc. (TRV) risen by +2.55% to $148.72. The U.S. insurer posted better-than-expected quarterly earnings, helping to reduce disaster-related expenses...

Related news

Oil Market Was On Hold, Gold Still Unsteady

In the face of doubt about the market and progression of the Covid-19 virus, oil ended in a distributed order. U.S. light crude WTI...

Dollar Appreciated Amid Uncertainty Regarding The Stimulus Plan

The EUR/USD rate rose by 0.02 percent on Monday, January 25, and the trading session ended at the 1.2169 marks. In turn, the dollar...

Intel (INTC) Failed To Save Itself Despite Stronger Results, Comcast (CMCSA) Stabilized Despite Delaying Bond Film

Intel Corporation (INTC) decreased by -9.29% to $56.66. Shares of designer, manufacturer, and seller of essential semiconductor technologies for the cloud, smart, and connected...

Travelers Companies (TRV) Rose While United Airlines (UAL) Fell After Quarterly Results

On Thursday, The Travelers Companies Inc. (TRV) risen by +2.55% to $148.72. The U.S. insurer posted better-than-expected quarterly earnings, helping to reduce disaster-related expenses...
- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here